Sukjoo Cho

Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy

Yeseul Kim, Y. Chae, Jonghanne Park, 2021, Heliyon.

Blood transfusions may adversely affect survival outcomes of patients with lung cancer: a systematic review and meta-analysis

A. Bharat, G. Cho, Y. Chae, 2021, Translational Lung Cancer Research.

Artificial Intelligence-based Radiomics in the Era of Immuno-oncology

M. Abazeed, Yeseul Kim, Y. Chae, 2022, The oncologist.

238 Meta-analysis on the incidence of hyperprogressive disease during immune checkpoint inhibitor therapy

Y. Chae, S. P. Hong, Y. Oh, 2021, Journal for ImmunoTherapy of Cancer.

Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC)

J. Y. Lee, Yeseul Kim, Y. Chae, 2020, Cancer Immunology, Immunotherapy.

519 Meta-analysis on immunotherapy-related hyperprogressive disease (HPD) incidence across tumor types and HPD definitions

Y. Chae, Y. Oh, Sukjoo Cho, 2022, Regular and Young Investigator Award Abstracts.